NEW YORK, NY / ACCESSWIRE / January 28, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS).

The report is available here: AMBS January 2016 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Highlights from the note are as follows:

Headway in commercialization and research

On January 19, 2016, the Company announced that it has entered into a letter of intent to merge Amarantus Diagnostics, its wholly-owned subsidiary, with Avant Diagnostics. The deal will allow them to progress at a much faster pace and to develop valuable diagnostic assets in areas of oncology and neurology. Both assets combined in a stand-alone diagnostics-focused entity have the potential to improve the practice of medicine by providing new proprietary diagnosis and monitoring tools for oncologists and neurologists.

Avant shall issue to Amarantus 80 million shares of common stock of Avant Diagnostics, encompassing approximately 45% of Avant's post-merger common stock, and 10 million additional shares of common stock upon achievement of certain sales milestones. Amarantus shall have the right to assign two directors to the Avant Board of Directors, and will support Avant in its product development and commercialization resources to further expand the development of the mutual product pipeline. The deal is expected to close in 2Q16 and is subject to customary closing conditions.

The Company stated that the merger will help to implement their goal of detecting early diseases in oncology and neurology and additional benefits by reducing costs and improving outcomes in the healthcare system.

Parallel agreement

Simultaneously, Amarantus Diagnostics has entered into an agreement with a Maryland-based CLIA laboratory to house its assays in preparation for CLIA-enabling validation studies. Upon closing of the merger transaction, Avant Diagnostics will take over this agreement and be positioned to complete the development of OvaDx in that CLIA-certified facility.

Please review important disclosures at www.seethruequity.com.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. AMBS' Therapeutics division has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson's disease levodopa-induced dyskinesia and with the potential to expand into adult ADHD and Alzheimer's aggression. The Company has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product in development for the treatment of severe burns currently preparing to enter Phase 2 clinical studies. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP). AMBS also owns the discovery of neurotrophic factors (PhenoGuard(TM)) that led to MANF's discovery.

AMBS' Diagnostics division owns the rights to MSPrecise(R), a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test(R)) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).

For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon

SeeThruEquity

info@seethruequity.com

SOURCE: SeeThruEquity